Payment overview · 2025
General Payments
$341.74
17 reported records · 9 companies
Healthcare provider profile · identity verified
Hillary Lunn, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BELL, FL · NPI 1598213423
Verified facts
What the public records show
CMS Open Payments records show Hillary Lunn, APRN received $341.74 in general payments during 2025 across 17 reported records.
Lilly USA, LLC accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.28 | 28.8% | 5 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $53.32 | 15.6% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $49.30 | 14.4% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $35.10 | 10.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.47 | 9.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.36 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.87 | 5.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.51 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.53 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.74 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $98.28 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.04 | 4 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $53.32 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $53.32 | 3 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $35.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 217 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 75 |
| Lisinopril | Lisinopril | 149 | 67 |
| Gabapentin | Gabapentin | 140 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 54 |
| Losartan Potassium | Losartan Potassium | 109 | 49 |
| Omeprazole | Omeprazole | 109 | 56 |
| Metformin Hcl | Metformin Hcl | 95 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 29 |
| Alprazolam | Alprazolam | 68 | 22 |
| Furosemide | Furosemide | 68 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 30 |
| Trazodone Hcl | Trazodone Hcl | 61 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 34 |
| Montelukast Sodium | Montelukast Sodium | 58 | 32 |
| Meloxicam | Meloxicam | 55 | 28 |
| Mupirocin | Mupirocin | 55 | 38 |
| Simvastatin | Simvastatin | 55 | 23 |
| Tramadol Hcl | Tramadol Hcl | 55 | 25 |
| Amoxicillin | Amoxicillin | 54 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 29 |
| Methylprednisolone | Methylprednisolone | 50 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 11 |
| Sertraline Hcl | Sertraline Hcl | 44 | 20 |
| Buspirone Hcl | Buspirone Hcl | 43 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Prednisone | Prednisone | 41 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 12 |
| Methocarbamol | Methocarbamol | 38 | 30 |
| Bupropion Xl | Bupropion Hcl | 37 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 30 |
| Potassium Chloride | Potassium Chloride | 36 | 17 |
| Glipizide | Glipizide | 35 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 18 |
| Azithromycin | Azithromycin | 30 | 29 |
| Cephalexin | Cephalexin | 29 | 25 |
| Eliquis | Apixaban | 29 | 12 |
| Jardiance | Empagliflozin | 28 | 18 |
| Fluconazole | Fluconazole | 27 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 15 |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Mounjaro | Tirzepatide | 27 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Famotidine | Famotidine | 25 | 16 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | 13 |
| Nystatin | Nystatin | 22 | 19 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 15 |
| Glimepiride | Glimepiride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | 13 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Ofloxacin | Ofloxacin | 17 | 16 |
| Ozempic | Semaglutide | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Acyclovir | Acyclovir | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.74 · 17 records | Lilly USA, LLC | ABRYSVO, COMIRNATY, Cologuard Collection Kit, DAYBUE, Extended Holter, Fluad, Flucelvax, MOUNJARO, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error